TP53 and neoplasm: Consistent with the cell assay results, tail vein injection of the p28-p53-CEABP1 protein demonstrated substantially greater inhibitory efficacy (p < 0.0001) against LS174T tumor growth than did p28-p53 protein treatment (Figure 7A,B).